Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
IMP9064 · 1 trial · 2 indications
Safety and tolerability as determined by the incidence of adverse events (AEs), including severe AEs and serious AEs (SAEs)
Maximum Tolerable Dose (if any)/Recommended Phase 2 Dose of IMP9064 monotherapy
| Arm | Type | Description |
|---|---|---|
| IMP9064 Monotherapy | EXPERIMENTAL | Dose-escalation IMP9064 administered orally on empty stomach once/twice daily |
| Name | Type | Description |
|---|---|---|
| IMP9064 | DRUG | IMP9064 Monotherapy administered for 21 days |
Inclusion Criteria: 1. Patients ≥ 18 years of age on the day of signing informed consent form (ICF) (at the time of screening for Part 1 and Part 2C and pre-screening for Part 2A and Part 2B). 2. Must voluntarily participate in the study and be willing and able to provide signed informed consent wh...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
IMP9064 is an investigational small molecule being studied for the treatment of advanced solid tumors. It is currently in Phase 1 clinical development as a monotherapy or in combination for patients with advanced solid tumors.
IMP9064 is being developed by cbdMD, Inc., a company traded on the NYSE American under the ticker YCBD. The drug is currently in Phase 1 clinical trials for advanced solid tumors.
IMP9064 is in Phase 1 clinical development. It is an investigational drug being studied in a Phase 1 trial for advanced solid tumors, and it has not yet been approved by regulatory authorities.
IMP9064 is being evaluated in a Phase 1 clinical trial with the identifier NCT05269316. This trial is recruiting patients with advanced solid tumors and is being conducted in the United States, Australia, China, and Taiwan.
IMP9064 is being studied both as a monotherapy and in combination with other agents in a Phase 1 clinical trial for advanced solid tumors. The trial is uncontrolled and is enrolling approximately 61 patients aged 18 years and older.